

Safety Data Sheet (SDS) According to the REACH Regulation (EC) No. 1907/2006

**Issuing Date:** 2018-03-23 **Revision Date:** 2024-03-26 **Version:** 2

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

## 1.1. Product identifier

Product No 5927

Product name Doxorubicin

## Contains

Chemical name Index No. (8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo Not Listed -hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-tr

ihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacen e-5,12-dione hydrochloride (90 - 100%)

Formula C27H30CINO11 Molecular Weight 579.98 g/mol

# 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Identified uses** For Research Use Only. Not for Use in Diagnostic Procedures.

# 1.3. Details of the supplier of the safety data sheet

Importer Manufacturer

Cell Signaling Technology Europe B.V. Cell Signaling Technology, Inc.

 Dellaertweg 9b
 3 Trask Lane

 2316 WZ Leiden
 Danvers, MA 01923

 The Netherlands
 United States

 TEL: +31 (0)71 7200 200
 TEL: +1 978 867 2300

FAX: +31 (0)71 891 0019 FAX: +1 978 867 2400

Website www.cellsignal.com E-mail Address info@cellsignal.eu

#### 1.4. Emergency telephone number

CHEMTREC 24 hours a day, 7 days a week, 365 days a year

+1 703 527 3887 (INTERNATIONAL) +1 800 424 9300 (NORTH AMERICA)

Europe 112

# **SECTION 2: Hazards identification**

# 2.1. Classification of the substance or mixture

Regulation (EC) No. 1272/2008

Acute oral toxicity	Category 4 - (H302)
Germ cell mutagenicity	Category 1B - (H340)
Carcinogenicity	Category 1B - (H350)
Reproductive toxicity	Category 1B - (H360FD)

#### 2.2. Label elements



## Signal word Danger

#### Hazard statement(s)

H302 - Harmful if swallowed.

H340 - May cause genetic defects.

H350 - May cause cancer.

H360FD - May damage fertility. May damage the unborn child.

# Precautionary statement(s)

P201 - Obtain special instructions before use.

P202 - Do not handle until all safety precautions have been read and understood.

P264 - Wash face, hands and any exposed skin thoroughly after handling.

P270 - Do not eat, drink or smoke when using this product.

P280 - Wear protective gloves/protective clothing/eye protection/face protection.

P301 + P312 - IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.

P308 + P313 - IF exposed or concerned: Get medical advice/attention.

P330 - Rinse mouth.

P405 - Store locked up.

P501 - Dispose of contents/container to an approved waste disposal plant.

# 2.3. Other hazards

No information available.

For the full text of the H-phrases & EUH-phrases mentioned in this Section, see Section 16

# **SECTION 3: Composition/information on ingredients**

# 3.1 Substances

**Synonyms** Doxorubicin Hydrochloride;

Adriamycin;

Antineoplastic antibiotic obtained from Streptomyces peucetius;

Lipodox

Formula C<sub>27</sub>H<sub>30</sub>CINO<sub>11</sub>

Chemical name	CAS No	Weight-%	EC No	Classification (1272/2008)	REACH Registration Number
(8S-cis)-10-((3-Amino-2,3 ,6-trideoxy-alpha-L-lyxo-h exopyranosyl)oxy)-7,8,9,		100	246-818-3	Acute Tox. 4 (H302) Muta. 1B (H340) Carc. 1B (H350) Repr. 1B (H360FD)	no data available

10-tetrahydro-6,8,11-trihy		STOT RE 2 (H373)	
droxy-8-(hydroxyacetyl)-1			
uroxy-o-(riyuroxyacetyi)- i			
-methoxynaphthacene-5,			
12-dione hydrochloride			
12-dione flydrochlonde			

For the full text of the R-phrases mentioned in this Section, see Section 16

## **SECTION 4: First aid measures**

# 4.1. Description of first aid measures

General advice Use first aid treatment according to the nature of the injury. When symptoms persist or in all

cases of doubt seek medical advice.

**Inhalation** Move to fresh air. Consult a physician.

Skin contact Take off contaminated clothing. Wash off immediately with plenty of water. Consult a

physician.

**Eye contact Ingestion**Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Clean mouth with water and afterwards drink plenty of water. Consult a physician.

#### 4.2. Most important symptoms and effects, both acute and delayed

Symptoms of overexposure may be headache, dizziness, tiredness, nausea and vomiting. May cause an allergic skin reaction including itching, redness, and rash.

# 4.3. Indication of any immediate medical attention and special treatment needed

Notes to physician Treat symptomatically.

# **SECTION 5: Firefighting measures**

## 5.1. Extinguishing media

Suitable Extinguishing Media Unsuitable Extinguishing Media

Dry chemical, CO<sub>2</sub>, water spray or alcohol-resistant foam

No information available

## 5.2. Special hazards arising from the substance or mixture

Thermal decomposition can lead to release of irritating gases and vapors.

Hazardous Combustion Products

Carbon oxides (COx), Nitrogen oxides (NOx), Hydrogen chloride

## 5.3. Advice for firefighters

Wear self-contained breathing apparatus and protective suit. Use personal protective equipment.

# **SECTION 6: Accidental release measures**

# 6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel Evacuate personnel to safe areas. Ensure adequate ventilation. Avoid dust formation. Avoid

contact with skin, eyes and clothing. Use personal protective equipment.

For emergency responders

Use personal protection recommended in Section 8.

#### 6.2. Environmental precautions

Do not flush into surface water or sanitary sewer system.

## 6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

Methods for cleaning up

Use personal protective equipment. Cover powder spill with plastic sheet or tarp to minimize

spreading and keep powder dry. Take up mechanically, placing in appropriate containers for

disposal. Avoid dust formation. Clean contaminated surface thoroughly.

# 6.4. Reference to other sections

See Sections 8 & 13 for additional information.

# **SECTION 7: Handling and storage**

#### 7.1. Precautions for safe handling

Use only in area provided with appropriate exhaust ventilation. Wear personal protective equipment. Avoid contact with skin, eyes and clothing. Avoid dust formation. Do not breathe dust. Wash thoroughly after handling.

## 7.2. Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

# 7.3. Specific end use(s)

Use as a laboratory reagent.

# **SECTION 8: Exposure controls/personal protection**

## 8.1. Control parameters

The product does not contain any hazardous materials with occupational exposure limits established.

# 8.2. Exposure controls

## Appropriate engineering controls

Showers, eyewash stations, and ventilation systems

#### Individual protection measures, such as personal protective equipment

**Eye/face protection** Tightly fitting safety goggles

**Skin protection** Wear protective gloves and protective clothing

Hand protection Impervious gloves

Other Impervious gloves Impervious clothing

protection

# **Environmental Exposure Controls**

No information available

# **SECTION 9: Physical and chemical properties**

#### 9.1. Information on basic physical and chemical properties

Solid - Crystalline Powder Physical state

Color Orange

No information available Odor

Remarks • Method Property Values No information available No information available pН No information available No information available Melting point/freezing point Boiling point or initial boiling point No information available No information available

and boiling range

Flash point No information available No information available. **Evaporation rate** No information available No information available No information available No information available **Flammability** Upper/lower flammability or No information available No information available

explosive limits

Vapor pressure No information available No information available Relative vapor density No information available No information available No information available No information available Density and/or relative density No information available Solubility Practically insoluble Partition coefficient: n-octanol/water No information available No information available **Autoignition temperature** No information available No information available No information available No information available. **Decomposition temperature Viscosity** No information available No information available **Explosive properties** No information available No information available **Oxidizing properties** No information available No information available

9.2. Other information

Softening point No information available

**Molecular Weight** 579.98 g/mol

Solubility in other solvents No information available No information available VOC content **Liquid Density** No information available

# **SECTION 10: Stability and reactivity**

#### 10.1. Reactivity

No information available.

#### 10.2. Chemical stability

Stable under normal conditions.

# 10.3. Possibility of hazardous reactions

Hazardous polymerization does not occur. Hazardous polymerization

**Hazardous reactions** None under normal processing

# 10.4. Conditions to avoid

None known based on information supplied

#### 10.5. Incompatible materials

Strong acids, Strong bases, Strong oxidizing agents, Strong reducing agents.

### 10.6. Hazardous decomposition products

None under normal use conditions

# **SECTION 11: Toxicological information**

## 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

This material should only be handled by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals. It should be borne in mind that the toxicological and physiological properties of this compound is not well defined.

Chemical name	LD50 Oral	LD50 Dermal	LC50 Inhalation
(8S-cis)-10-((3-Amino-2,3,6-trideoxy	698 mg/kg ( Mouse )	-	-
-alpha-L-lyxo-hexopyranosyl)oxy)-7,			
8,9,10-tetrahydro-6,8,11-trihydroxy-			
8-(hydroxyacetyl)-1-methoxynaphth			
acene-5,12-dione hydrochloride			

#### **Unknown Acute Toxicity**

No information available.

#### Information on likely routes of exposure

InhalationThere is no data available for this product.Eye contactThere is no data available for this product.Skin contactThere is no data available for this product.

**Ingestion** May be harmful if swallowed.

Symptoms Symptoms of overexposure may be headache, dizziness, tiredness, nausea and vomiting.

May cause an allergic skin reaction including itching, redness, and rash.

Skin corrosion/irritation
Serious eye damage/eye irritation
Sensitization
No information available.
No information available.
No information available.

Mutagenic effects In vitro tests have shown mutagenic effects. Some in vivo tests have shown mutagenic

effects. Mutagenic in vitro in the bacterial reverse mutation assays (AMES test).

Carcinogenicity Laboratory experiments on animals have reported the development of tumors. Listed as

probable human carcinogen by IARC (Group 2A).

production that the control of the c					
Chemical name	European Union	IARC			
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo		Group 2A (Adriamycin)			
-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-tr					
ihydroxy-8-(hydroxyacetyl)-1-methoxynaphthace					
ne-5,12-dione hydrochloride					

#### Legend:

IARC: (International Agency for Research on Cancer) Group 2A - Probably Carcinogenic to Humans

Reproductive toxicity Experiments have shown reproductive toxicity effects on laboratory animals. May damage

fertility or the unborn child.

STOT - single exposure

No information available.

STOT - repeated exposure May cause damage to organs through prolonged or repeated exposure.

Target Organ Effects Heart, Liver, Reproductive system.

Aspiration Hazard No information available.

#### 11.2. Information on other hazards

No information available.

# **SECTION 12: Ecological information**

## 12.1. Toxicity

No information available.

# 12.2. Persistence and degradability

No information available

## 12.3. Bioaccumulative potential

Bioaccumulation No information available.

No information available. **Bioconcentration factor (BCF)** 

# 12.4. Mobility in soil

No information available.

#### 12.5. Results of PBT and vPvB assessment

No information available.

# 12.6. Endocrine disrupting properties

This product does not contain any known or suspected endocrine disruptors

#### 12.7. Other adverse effects

No information available

# **SECTION 13: Disposal considerations**

## 13.1. Waste treatment methods

Waste from residues / unused

products

Dispose of in accordance with local regulations.

Contaminated packaging

Empty containers should be taken to an approved waste handling site for recycling or

disposal.

Other information

According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user based on the application

for which the product was used.

# **SECTION 14: Transport information**

# IMDG/IMO

14.1 UN number Not regulated 14.2 UN proper shipping name Not regulated 14.3 Transport hazard class(es) Not regulated Not regulated

14.4 Packing group 14.5 Environmental hazards

None

14.6 Special precautions for user

None

14.7 Maritime transport in bulk according to IMO instruments

Not regulated

## ADR/RID

14.1 UN number Not regulated
14.2 UN proper shipping name
14.3 Transport hazard class(es)
14.4 Packing group Not regulated
14.5 Environmental hazards
14.6 Special precautions for user

**IATA** 

14.1 UN number
Not regulated
None
None
None

# **SECTION 15: Regulatory information**

#### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

# Registration, Evaluation, Authorization and Restriction of Chemicals (REACH)

This product does not contain Substances of Very High Concern (SVHC).

#### **SEVESO Directive Information**

This product does not contain substances identified in the SEVESO Directive.

#### International inventories

TSCA 8(b) - DSL/NDSL -

EINECS/ELINCS Complies

ENCS -

IECSC -

**KECL** Complies

PICCS - AICS -

#### International inventories legend

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

**EINECS/ELINCS** - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

**KECL** - Korean Existing and Evaluated Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

## 15.2. Chemical safety assessment

For this substance a chemical safety assessment has not been carried out

# **SECTION 16: Other information**

# Full text of H-Statements referred to under Sections 2 and 3

H302 - Harmful if swallowed

H340 - May cause genetic defects if inhaled

#### 5927 Doxorubicin

H350 - May cause cancer if swallowed

H360FD - May damage fertility. May damage the unborn child

Classification procedure: Expert judgment and weight of evidence determination.

 Issuing Date:
 2018-03-23

 Revision Date:
 2024-03-26

**Disclaimer** 

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.